Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 578-588

  Feng, Yan Bin ^a   Lin, De Chen ^a   Shi, Zhi Zhou ^a   Wang, Xiao Chun ^a   Shen, Xiao Ming ^a   Zhang, Yu ^a   Du, Xiao Li ^a   Luo, Man Li ^a   Xu, Xin ^a   Han, Ya Ling ^a   Cai, Yan ^a   Zhang, Zi Qiang ^a   Zhan, Qi Min ^a   Wang, Ming Rong ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Esophageal squamous cell carcinoma; PLK1; Prognosis; Survivin

Indexed keywords

CASPASE 9; MESSENGER RNA; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN MCL 1; SURVIVIN; BIRC5 PROTEIN, HUMAN; CELL CYCLE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; BIOSYNTHESIS; CONFOCAL MICROSCOPY; ESOPHAGUS TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; MORTALITY; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149294015     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23990     Document Type: Article

References (41)

1. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-30.
2. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004;279:25549-61.
3. Tsvetkov L, Xu X, Li J, Stern DF. Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody. J Biol Chem 2003;278:8468-75.
4. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nish-ida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001;410:215-20.
5. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997;234:397-405.
6. Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C, Sakano S, Furuya T, Oga A, Naito K, Sasaki K. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006;70:231-7.
7. Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A, Ozaki M, Ito H, Ikeguchi M. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006;70:126-33.
8. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M, Dietel M, Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004;90:815-21.
9. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S. Polo-like kinase 1 (PLK1) is overex- pressed in primary colorectal cancers. Cancer Sci 2003;94:148-52.
10. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Muller BM, Niesporek S, Dietel M, Denkert C. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005;446:442-50.
11. Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, Milan G, Man- druzzato S, Del Bianco P, Ruol A, Zaninotto G, Zanovello P. Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 2006;119:1717-22.
12. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kauf- mann M, Strebhardt K. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006;66:5836-46.
13. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe plk1 depletion. Mol Cell Biol 2006;26:2093-108.
14. Zhou Q, Bai M, Su Y. Inhibition of expression of polo-like kinase 1 by RNAi interference in A549 cells. Chin J Biochem Mol Biol 2005; 21:665-72.
15. van Vugt MA, van de Weerdt BC, Vader G, Janssen H, Calafat J, Klompmaker R, Wolthuis RM, Medema RH. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004;279:36841-54.
16. Almeida A, Bolanos JP, Medina JM. Nitric oxide mediates glutamate- induced mitochondrial depolarization in rat cortical neurons. Brain Res 1999;816:580-6.
17. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007;282:26202-9.
18. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000;97:13103-7.
19. Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N. Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer. Ann Thorac Surg 2000;70:913-17.
20. Ikeguchi M, Sakatani T, Ueta T, Kaibara N. Cyclin D1 expression and retinoblastoma gene protein (pRB) expression in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2001;127:531-6.
21. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M, Shimada Y. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:2597-605.
22. Tong T, Zhong Y, Kong J, Dong L, Song Y, Fu M, Liu Z, Wang M, Guo L, Lu S, Wu M, Zhan Q. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:7304-10.
23. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998;21:177-84.
24. Wei F, Ni J, Wu SS, Liu H, Xu X, Han YL, Cai Y, Zhang JW, Chen XJ, Pang H, Lu N, Ji L, et al. Cytogenetic studies of esophageal squamous cell carcinomas in the northern Chinese population by comparative genomic hybridization. Cancer Genet Cytogenet 2002;138:38-43.
25. Nakao K, Shibusawa M, Tsunoda A, Yoshizawa H, Murakami M, Kusano M, Uesugi N, Sasaki K. Genetic changes in primary colorectal cancer by comparative genomic hybridization. Surg Today 1998;28:567-9.
26. Gebhart E, Liehr T, Wolff E, Ries J, Fiedler W, Steininger H, Koscielny S, Girod S. Pattern of genomic imbalances in oral squamous cell carcinomas with and without an increased copy number of 11q13. Int J Oncol 1998;12:1151-5.
27. Kang JU, Kang JJ, Kwon KC, Park JW, Jeong TE, Noh SM, Koo SH. Genetic alterations in primary gastric carcinomas correlated with clinicopathological variables by array comparative genomic hybridization. J Korean Med Sci 2006;21:656-65.
28. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999;15:687-92.
29. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789-94.
30. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94:1863-77.
31. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. Faseb J 2005;19:611-13.
32. Fan Y, Zheng S, Xu ZF, Ding JY. Apoptosis induction with polo-like kinase-1 antisense phosphorothioate oligodeoxynucleotide of colon cancer cell line SW480. World J Gastroenterol 2005;11:4596-9.
33. Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2004;279:2077-84.
34. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981-90.
35. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells. Oncogene 2004;23:39-48.
36. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003;9:2683-92.
37. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54.
38. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003;63:230-5.
39. Zhou J, O'Brate A, Zelnak A, Giannakakou P. Survivin deregulation in (β-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res 2004;64:8708-14.
40. Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, Altieri DC. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001;108:991-9.
41. Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, Mohammad D, Cantley LC, Smerdon SJ, Yaffe MB. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the polo-box domain. Cell 2003;115:83-95.